Eisai chief outlines Belviq sales effort, deal strategy

Eisai's chief executive has mapped out a three-prong strategy for marketing the new diet drug Belviq in early 2013. Haruo Naito says Eisai will work on patient education, enhancing disease awareness and collaborations with patient groups as it starts to campaign for insurance coverage. Naito, though, was unwilling to tell Dow Jones what it will charge for the treatment, though some analysts expect to see a price tag of around $3.50 a day. He also said that Eisai is interested in pursuing other deals on oncology, neuroscience and immunology that would be similar to the $325 million acquisition of Morphotek in 2007. Story

Like what you're reading?
Click here to get more news like this delivered to your inbox everyday>>

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.